Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Glaukos's Average Total Inventories for the quarter that ended in Mar. 2026 was €54.1 Mil. Glaukos's Revenue for the
three
months ended in Mar. 2026 was €130.2 Mil.
Glaukos's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.42.
Glaukos's Inventory-to-Revenue for the quarter that ended in Mar. 2026
declined
from Dec. 2025 (0.45) to Dec. 2025 (0.42)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Glaukos's Days Inventory for the
three
months ended in Mar. 2026 was 171.26.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Glaukos's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.53.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Glaukos's Days Inventory for the
three
months ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos Inventory-to-Revenue Related Terms
Glaukos Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Glaukos's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6GJ vs LIVN, BIO, IRTC: Inventory-to-Revenue Comparison
For the Medical Devices subindustry, Glaukos's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Inventory-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Glaukos's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Glaukos's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (STU:6GJ) has a Inventory-to-Revenue of 0.42 as of Mar. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Glaukos and its competitors.
Is Glaukos' Inventory-to-Revenue too high?
Glaukos' current Inventory-to-Revenue is 0.42. Overall, Glaukos has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Inventory-to-Revenue compare to LIVN and BIO?
Glaukos' Inventory-to-Revenue of 0.42 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Medical Devices & Instruments company?
A good Inventory-to-Revenue depends on the Medical Devices & Instruments industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Glaukos and its competitors. Glaukos's current Inventory-to-Revenue is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (STU:6GJ) is currently considered Fairly Valued. The stock's GF Value™ is €118.60, compared to a current price of €118.00 — trading 0.5% below its estimated fair value. The current Inventory-to-Revenue is 0.42. Glaukos' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Glaukos (STU:6GJ), the current Inventory-to-Revenue is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (STU:6GJ) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be undervalued.
The current stock price of €118.00 is trading 0.5% below its estimated GF Value™ of €118.60.
GuruFocus considers Glaukos to be Fairly Valued.
Key valuation signals for STU:6GJ:
Inventory-to-Revenue: 0.42
GF Value™: €118.60 vs. price of €118.00 (0.5% below fair value)
No single metric tells the full story. See the STU:6GJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score
Get the complete analysis for STU:6GJ
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6GJ has been successfully added to your 
